Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

[Hepatocellular carcinoma: what's new?].

Teufel A, Marquardt JU, Galle PR, Wörns M.

Dtsch Med Wochenschr. 2012 Feb;137(5):210-3. doi: 10.1055/s-0031-1292890. Epub 2012 Jan 16. Review. German. No abstract available.

PMID:
22250042
2.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

3.

Review article: the management of hepatocellular carcinoma.

Cabrera R, Nelson DR.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76. doi: 10.1111/j.1365-2036.2009.04200.x. Epub 2009 Nov 19. Review.

4.

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V.

J Hepatol. 2010 May;52(5):771-5. doi: 10.1016/j.jhep.2010.01.025. Epub 2010 Mar 4.

5.

Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.

Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM.

J Gastroenterol Hepatol. 2011 Nov;26(11):1612-8. doi: 10.1111/j.1440-1746.2011.06751.x.

PMID:
21517968
6.

Major achievements in hepatocellular carcinoma.

Bruix J, Llovet JM.

Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. No abstract available.

PMID:
19231618
7.

[The treatment of hepatocellular carcinoma. New developments].

Kuiken SD, van Delden OM, Richel DJ, Jansen PL.

Ned Tijdschr Geneeskd. 2009 Apr 4;153(14):668-72. Review. Dutch. No abstract available.

PMID:
19425326
8.

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.

Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20.

PMID:
22265328
9.

Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.

Bathaix F, Marion D, Cuinet M, Maillard E, Zoulim F, Mornex F, Merle P.

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):314-8. doi: 10.1016/j.gcb.2010.01.015. Epub 2010 Mar 5.

10.

Closing remarks.

Kudo M.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:52. doi: 10.2165/1163025-S0-000000000-00000. No abstract available.

PMID:
22873627
11.

[Prospect of hepatocellular carcinoma in 2008].

Ye SL.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jan;17(1):7-9. Chinese. No abstract available.

PMID:
19391280
12.
13.

Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?

Di Benedetto F, Berretta M, De Ruvo N, Tarantino G, D'Amico G, Ballarin R, Iemmolo RM, Gerunda GE.

J Surg Oncol. 2012 Jan;105(1):111-2. doi: 10.1002/jso.22039. Epub 2011 Jul 25. No abstract available.

PMID:
21792942
14.

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E.

Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. No abstract available.

PMID:
20113152
15.

Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

Daniele B, Di Maio M.

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6. No abstract available.

PMID:
19564813
16.

Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.

Hussain K, El-Serag HB.

Minerva Gastroenterol Dietol. 2009 Jun;55(2):123-38. Review.

PMID:
19305372
17.

[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].

Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL.

Zhonghua Zhong Liu Za Zhi. 2010 Aug;32(8):630-3. Chinese.

PMID:
21122420
18.

Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.

Di Benedetto F, Tarantino G, Montalti R, Ballarin R, D'Amico G, Berretta M, Gerunda GE.

Transpl Int. 2011 Nov;24(11):e97; author reply e98-9. doi: 10.1111/j.1432-2277.2011.01329.x. Epub 2011 Sep 13. No abstract available.

19.

[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].

Li Y, Huang JW, Lu LG, Shao PJ, Hu BS, Huang GM, Wei ZG, Zhang L.

Zhonghua Yi Xue Za Zhi. 2010 Aug 17;90(31):2187-92. Chinese.

PMID:
21029658
20.

Diagnostic and prognostic molecular markers in hepatocellular carcinoma.

Mínguez B, Lachenmayer A.

Dis Markers. 2011;31(3):181-90. doi: 10.3233/DMA-2011-0841. Review.

Items per page

Supplemental Content

Write to the Help Desk